Press Releases

INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

Posted on November 23, 2020

INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting

Posted on November 20, 2020

INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense

Posted on November 16, 2020

INOVIO Reports Third Quarter 2020 Financial Results

Posted on November 9, 2020

INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020

Posted on October 26, 2020

INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800

Posted on September 28, 2020

INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium

Posted on September 8, 2020

INOVIO to Present at Upcoming Investor Conferences in September

Posted on September 1, 2020

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.